VITRAVENE PRESERVATIVE FREE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VITRAVENE PRESERVATIVE FREE is an injectable small-molecule antiviral approved in 1998 for intraocular administration. The preservative-free formulation eliminates potential irritants from chronic intravitreal delivery. Specific mechanism and indications are not publicly detailed in available records.
LOE Approaching
Product is in late-stage lifecycle with low current commercial pressure (30/100), indicating a contracted or transitional team focused on maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VITRAVENE PRESERVATIVE FREE offers limited growth trajectory but provides stability in a niche ophthalmology market with predictable patient populations. Roles emphasize account retention, managed care negotiation, and transition planning rather than market expansion.
Regional Sales ManagerAccount Manager (specialty pharmacy)
Worked on VITRAVENE PRESERVATIVE FREE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.